ArticleClinical and molecular hepatology2020
Clinical application of ultrasonography-guided percutaneous liver biopsy and its safety over 18 years.
Article in Clinical and molecular hepatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 29 citations in OpenAlex.
- European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) steatotic liver disease special interest group position paper on screening, diagnosis and investigation of paediatric metabolic dysfunction-associated steatotic liver disease.Journal of pediatric gastroenterology and nutrition · 2026Article
- Iodized oil marking guided biopsy of hepatic space-occupying lesions under the protection of hepatic artery catheterization.BMC cancer · 2025Article
- Improving diagnostic accuracy in cirrhotic patients: a comprehensive multicenter analysis of contrast-enhanced ultrasound-guided biopsy in a large cohort of 2056 patients.La Radiologia medica · 2025Article
- Deep Learning to Localize Photoacoustic Sources in Three Dimensions: Theory and Implementation.IEEE transactions on ultrasonics, ferroelectrics, and frequency control · 2025Article
- A review of image guidance and localization methods for liver puncture robots.Journal of robotic surgery · 2025Review
- Current Trends and Impact of Liver Biopsy on Survival in Hepatocellular Carcinoma: A Korean Multicenter Analysis.Diagnostics (Basel, Switzerland) · 2025Article
- Unravelling risk factors for delayed bleeding following ultrasonography-guided liver biopsy: a retrospective analysis.Translational gastroenterology and hepatology · 2025Article
- Highest 3-month international normalized ratio (INR): a predictor of bleeding following ultrasound-guided liver biopsy.European radiology · 2024Article
- Complication Rate after Percutaneous Liver Biopsy Using a Real-time Ultrasound Approach and Introducing a Uniform Methodology: A Brief Report.Iranian journal of medical sciences · 2024Article
- The Diagnostic Value of Liver Biopsy for Unexplained Liver Dysfunction: A Retrospective Study.Journal of multidisciplinary healthcare · 2024Article
- Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase.Clinical and molecular hepatology · 2023Article
- MRE-based NASH score for diagnosis of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease.Hepatology international · 2022Article
- Controlled attenuation parameter measured using transient elastography for the noninvasive assessment of macrovesicular steatosis in potential living liver donors.Ultrasonography (Seoul, Korea) · 2022Article
- The Diagnostic Accuracy of LOGIQ S8 and E9 Shear Wave Elastography for Staging Hepatic Fibrosis, in Comparison with Transient Elastography.Diagnostics (Basel, Switzerland) · 2021Article
- Controlled attenuation parameter value and the risk of hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy.Hepatology international · 2021Article
- Circulating miRNA is a useful diagnostic biomarker for nonalcoholic steatohepatitis in nonalcoholic fatty liver disease.Scientific reports · 2021Article
- Parenchymal Extinction Mimicking Hepatocellular Carcinoma in a Patient with Chronic Hepatitis B-Related Liver Cirrhosis.Diagnostics (Basel, Switzerland) · 2021Article
- Liver stiffness by magnetic resonance elastography is associated with increased risk of cardiovascular disease in patients with non-alcoholic fatty liver disease.Alimentary pharmacology & therapeutics · 2021Article
- Non-invasive assessment of cirrhosis using multiphasic dual-energy CT iodine maps: correlation with model for end-stage liver disease score.Abdominal radiology (New York) · 2021Article
- Serum lipocalin-2 is a potential biomarker for the clinical diagnosis of nonalcoholic steatohepatitis.Clinical and molecular hepatology · 2021Article
Corrections and comments
- Commented on by
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsLiver biopsy (LB) remains the gold standard for the evaluation of liver disease. However, over the past two decades, many noninvasive tests have been developed and utilized in clinical practice as alternatives to LB. The aim of this study was to evaluate the clinical use and safety of LB in the era of noninvasive assessment of liver fibrosis.
methodsThis retrospective study included 1,944 consecutive cases of LB performed between 2001 and 2018 in a tertiary hospital. All of the LBs were conducted under ultrasonography guidance with 18-gauge cutting needles.
resultsLBs were performed an average of approximately 108 times per year during the study period. Chronic hepatitis B (25.3%) and suspected malignancy (20.5%) were the two most common indications for LB. The use of LB for nonalcoholic fatty liver disease increased from 8.1% to 17.2% in the past 5 years compared to the last 10 years, while that for viral hepatitis decreased from 40.3% to 18.9%. Discordance rate between the suspected diagnosis and the final diagnosis was 2.6% (51 cases). The overall rate of major adverse events was 0.05% (one case), which involved delayed bleeding at the biopsy site. Liver cirrhosis was observed in 563 cases (28.9%), and the presence of cirrhosis did not affect the frequency of complications (P=0.289).
conclusionLB is widely used in clinical practice as an irreplaceable diagnostic tool, even in the era of noninvasiveness. Ultrasonography-guided LB can be performed safely in patients with liver cirrhosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.